Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Net Income	-48.07	-38.01
Depreciation & Amortization	0.37	0.16
Asset Writedown & Restructuring Costs	0.15	-
Stock-Based Compensation	1.22	2.24
Other Operating Activities	15.72	-
Change in Accounts Receivable	0.23	-0.23
Change in Accounts Payable	-0.72	-0.47
Change in Income Taxes	0.45	0.47
Change in Other Net Operating Assets	1.17	1.34
Operating Cash Flow	-29.49	-34.51
Sale of Property, Plant & Equipment	4	-
Cash Acquisitions	1.91	-
Other Investing Activities	0.04	-0
Investing Cash Flow	5.95	-0
Short-Term Debt Issued	6	-
Total Debt Issued	6	-
Net Debt Issued (Repaid)	6	-
Issuance of Common Stock	20	0.51
Other Financing Activities	-	-0.62
Financing Cash Flow	26	-0.1
Foreign Exchange Rate Adjustments	0.03	-
Net Cash Flow	2.49	-34.62
Cash Income Tax Paid	0.37	0.24
Levered Free Cash Flow	-3.25	-
Unlevered Free Cash Flow	-3.25	-
Change in Net Working Capital	-17.2	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.